In our study, we developed 2 distinct SR GVHD models: an ex vivo coculture system using intestinal organoids cultured with GR-deficient T cells and an in vivo BMT model of moderate GVHD severity with daily MP treatment initiated after the onset of symptoms. Here, NR3C1 is linked to graft versus host disease.